Gene therapy for rare blindness passes 5-year safety check

NCT ID NCT03597399

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study followed 87 people who had already received Luxturna gene therapy for a rare inherited eye condition that can cause blindness. The goal was to watch for any side effects over 5 years after treatment. No new treatment was given; researchers simply collected safety information to better understand the long-term risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONFIRMED BIALLELIC RPE65 MUTATION-ASSOCIATED RETINAL DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bascom Palmer Eye Institute

    Miami, Florida, 33136, United States

  • Casey Eye Institute

    Portland, Oregon, 97239, United States

  • Children's Hospital of Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Eye Institute

    Cincinnati, Ohio, 45242, United States

  • Cullen Eye Institute

    Houston, Texas, 77030, United States

  • Kellogg Eye Center

    Ann Arbor, Michigan, 48105, United States

  • Massachusetts Eye and Ear Institute

    Boston, Massachusetts, 02114, United States

  • Scheie Eye Institute

    Philadelphia, Pennsylvania, 19104, United States

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.